News

Our highlights from March 2023 included a teaser episode of a new KOL-led podcast, a feature elucidating a rare eye disease, and a look at the development of new therapies for geographic atrophy.

New data quantify the exposure to wildfire particulate matter among schoolchildren in California, finding that interventions in a small number of schools may reduce the overall burden of wildfire PM2.5 exposure.

Although 75% of gastroenterologists believed that the efficacy of biosimilars and biologics were the same, most clinicians still preferred the brand-name drug option.

A recent analysis suggests cardiovascular and socioeconomic factors explain one‐quarter of the racial and ethnic differences in arterial stiffness of youth with type 1 diabetes.

Results reveal changes in sleep problems across adolescence are associated with internalizing and externalizing symptoms, highlighting the need to address this early.

Patients who received the biosimilar reported early and significant improvements in areas of pain, NSAIDs requirement, and function.

Leveraging data from the PADIT trial, investigators provide an overview of the impact of extent and timing of infections following cardiac implantable electronic device implantation.

The incidence of mPDAI-defined remission at week 14 was 31% in the vedolizumab group, compared to 10% in the placebo group.

A new study in China showed that a combination of mask and serum containing both salicylic acid and lipohydroxy acid showed improvement in acne.

New data from a study in Egypt suggests that several key factors contribute to some of the negative impacts of psoriasis on mothers of children with the skin condition.

The majority of patients felt it was important for healthcare providers talk to them about the symptoms, possible treatments. In addition, most patients are not prescribed a medication right away.

In families carrying very rare AMD-causing variants, the analysis found two proteins that may be the driving force behind AMD pathology in affected patients.

New data demonstrate suvorexant and lemborexant were equally effective in improving sleep status, but lemborexant may cause side effects less frequently.

A systematic review and meta-analysis found the prevalence of diabetes increases with COVID-19 severity, with diabetes accounting for 9.5% of severe COVID-19 cases and 16.8% of deaths.

The petition with the US DEA is aiming to remove dual orexin receptor antagonist medications from the Controlled Substances Act due to negligible potential for abuse.

The proportion of AUD treatment engagement did not differ between the 2 time periods, but intervention increased intermediate outcomes, including screening, new AUD diagnosis, and treatment initiation.

This new data investigated the impacts of social, cultural, and community engagement by adults 50 and older on health care utilization.

Data from a recent study suggests statin-associated muscle symptoms were not exacerbated as a result of moderate-intensity physical activity.

Among 1660 cases with only PCR data, the cycle threshold was significantly associated with recurrence-free survival.

An analysis of data from more than 10,000 individuals in Europe sheds new light on risk of arterial stiffness associated with excess sodium intake.

A set of highlights from some of the impactful breakthroughs covered in dermatology this past month, including phase 3 trial data bimekizumab, tapinarof, and other treatments.

The presence of IRF at baseline harmed treatment response, while other factors were negligible on how well patients with nAMD responded to a loading dose of aflibercept.

The monthly prophylactic injection reduces bleeds by interfering with the production of specific proteins for both types of hemophilia with or without inhibitors.

The reduced dosing of azithromycin supports its use as an alternative to doxycycline for at least 6 weeks in patients with moderate to severe meibomian gland dysfunction.

New data suggest that older dementia patients who also have dementia are recommended to take apixaban, an oral anticoagulant.

Data from the CLVer trial provide insight into the effects of verapamil use on beta cell function among a cohort of children and adolescents with newly diagnosed type 1 diabetes.

A nearly two-fold increase or decrease in liver stiffness would be required to confidently represent a change in the underlying fibrosis.

There were few or no studies investigating education and training, personal protective equipment or monitoring, and evaluation of interventions.